α-Glucosidase-IN-20 (Compound 3B) is a highly effective and orally active inhibitor of α-glucosidase. It exhibits potent anti-diabetic properties, as evidenced by its IC50 value of 3.01 μM [1].

α-Glucosidase-IN-20 (Compound 3B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin -induced diabetic rats [1]. α-Glucosidase-IN-20 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats [1]. α-Glucosidase-IN-20 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice [1]. Animal Model: Male Wistar albino rats (170-200 g), Streptozotocin-induced diabetes model [1] Dosage: 10 and 20 mg/kg Administration: Oral administration; daily, for 4 weeks Result: Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers.